43 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28103022	36	Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.	Vanderbilt University
27161876	41	Design, synthesis, structure-activity relationships, and docking studies of pyrazole-containing derivatives as a novel series of potent glucagon receptor antagonists.	Shanghai Institute Of Materia Medica
26303893	93	A novel series of indazole-/indole-based glucagon receptor antagonists.	Merck Research Laboratories
26271588	19	Recent progress in the development of small-molecule glucagon receptor antagonists.	Pfizer
25127101	26	Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.	Dainippon Sumitomo Pharma
24881566	140	Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).	Glaxosmithkline
24527772	262	The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.	Merck Research Laboratories
23562063	32	The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.	Pfizer
22650618	4	Rediocide A, an Insecticide, induces G-protein-coupled receptor desensitization via activation of conventional protein kinase C.	Chinese Academy Of Sciences
22708876	106	Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.	Merck Research Laboratories
19597507	62	A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.	Indiana University
19702274	31	Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.	Bristol-Myers Squibb
22119466	38	A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.	Pfizer
22030028	55	Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.	Merck Research Laboratories
22001094	78	Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.	Merck Research Laboratories
21147532	82	Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.	Merck Research Laboratories
20813948	63	Spiroindolones, a potent compound class for the treatment of malaria.	Swiss Tropical And Public Health Institute
18707090	68	Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.	Novo Nordisk
18539028	81	Discovery of potent, orally active benzimidazole glucagon receptor antagonists.	Merck Research Laboratories
15387654	3	BI-32169, a bicyclic 19-peptide with strong glucagon receptor antagonist activity from Streptomyces sp.	Boehringer Ingelheim Pharma Gmbh And
17201415	47	New beta-alanine derivatives are orally available glucagon receptor antagonists.	Novo Nordisk
17126016	69	Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor.	Merck Research Laboratories
16500101	3	Novel substituted naphthalen-1-yl-methanone derivatives as anti-hyperglycemic agents.	Central Drug Research Institute
16250656	4	Fast small molecule similarity searching with multiple alignment profiles of molecules represented in one-dimension.	Pharmacopeia
16102966	55	Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.	Merck Research Laboratories
15713396	22	Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.	Merck Research Laboratories
15080976	43	Biaryl amide glucagon receptor antagonists.	Abbott Laboratories
12477359	78	Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.	Novo Nordisk
12419375	21	Integration of optimized substituent patterns to produce highly potent 4-aryl-pyridine glucagon receptor antagonists.	Bayer Research Center
11965376	19	Optimization of the 4-aryl group of 4-aryl-pyridine glucagon antagonists: development of an efficient, alternative synthesis.	Bayer Research Center
11844695	35	Human glucagon receptor antagonists based on alkylidene hydrazides.	Pfizer
11814820	28	Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists.	Bayer Research Center
11549467	85	Substituted imidazoles as glucagon receptor antagonists.	Merck Research Laboratories
11543683	42	Identification of alkylidene hydrazides as glucagon receptor antagonists.	Pfizer
10201821	166	Potent, orally absorbed glucagon receptor antagonists.	Merck Research Laboratories
9857085	33	Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists.	Novo Nordisk
28376304	26	Origins of PDZ Binding Specificity. A Computational and Experimental Study Using NHERF1 and the Parathyroid Hormone Receptor.	The University Of Queensland
21108268	67	Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.	Eberhard Karls University Of Tuebingen